Allergy Immunotherapy Global Market Report 2024

“Allergy Immunotherapy Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on allergy immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for allergy immunotherapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The allergy immunotherapy market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Allergy Type: Allergic Rhinitis; Asthma; Food Allergy; Venom Allergy; Other Allergy Types
• 2) By Treatment: Subcutaneous Immunotherapy (SCIT); Sublingual Immunotherapy; Specific Immunotherapy (SIT)
• 3) By Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Companies Mentioned: LETI Pharma; Stallergenes Greer International AG; Allergy Therapeutics plc; ALK-Abello A/S; HAL Allergy B.V.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Allergy immunotherapy is a therapeutic approach designed to mitigate allergic reactions to substances such as house dust mites, grass pollen, and bee venom. This treatment involves gradually administering increasing doses of the specific chemical or allergen to which the patient is allergic.

The primary allergy types addressed through allergy immunotherapy include allergic rhinitis, asthma, food allergies, venom allergies, and others. Allergic rhinitis pertains to a diagnosis encompassing a set of symptoms that impact the nose. Various treatment modalities include subcutaneous immunotherapy (SCIT), sublingual immunotherapy, and specific immunotherapy (SIT). These treatments can be accessed through different channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The allergy immunotherapy market research report is one of a series of new reports from The Business Research Company that provides allergy immunotherapy market statistics, including the allergy immunotherapy industry global market size, regional shares, competitors with allergy immunotherapy market share, detailed allergy immunotherapy market segments, market trends, and opportunities, and any further data you may need to thrive in the allergy immunotherapy industry. This allergy immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The allergy immunotherapy market size has grown rapidly in recent years. It will grow from $2.59 billion in 2023 to $2.86 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth observed during the historical period can be attributed to several factors, including the rising incidence of allergic diseases, advancements in immunotherapy techniques, an increasing awareness among patients regarding allergy management, government initiatives supporting healthcare, and improvements in research and development efforts within the field.

The allergy immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $4.43 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The anticipated growth in the forecast period can be attributed to several factors, including the escalating global burden of allergies, support from healthcare policies, a growing acceptance of immunotherapy, opportunities in emerging markets and untapped regions, and an overall increase in healthcare expenditure. Key trends expected in the forecast period encompass advancements in treatment technology, a continuous rise in allergy prevalence, an increase in patient awareness and education, the growing influence of telemedicine and remote monitoring, and the development of customized treatment plans.

The projected surge in the prevalence of allergic disorders is poised to be a significant driver propelling growth within the allergy immunotherapy market. Allergic disorders denote excessive immune responses triggered by specific antigens, resulting in conditions such as IgE-mediated allergic rhinitis and allergic asthma. Allergy immunotherapy caters to atopic individuals grappling with such disorders, often induced by inhaled allergens such as pollens and house dust mites (HDMs). As per the Centers for Disease Control and Prevention (CDC), nearly one-third of US adults, aged 18 and above, encountered seasonal allergies, skin conditions, or food allergies in 2021. Seasonal allergies notably dominated, affecting approximately 25.7% of adults, followed by eczema (7.3%) and food allergies (6.2%). The rising prevalence, particularly across diverse age groups and gender disparities, underscores the driving force behind the expansion of the allergy immunotherapy market.

The escalating consumption of alcohol is anticipated to fuel growth within the allergy immunotherapy market. Ethyl alcohol or ethanol, found in alcoholic beverages, such as red wine, contains histamine, contributing to allergy-such as symptoms. Allergy immunotherapy treatments are sought for mitigating such allergic reactions induced by histamine in alcohol. For instance, a report by Kirin Holdings Company Limited revealed a significant global increase in beer consumption, reaching around 185.60 million kiloliters in 2021, marking a 4.0% rise from the preceding year. This surge in alcohol consumption, paired with the presence of allergens such as histamine in certain beverages, is identified as a driving force for the allergy immunotherapy market.

The burgeoning healthcare expenditure is poised to drive the expansion of the allergy immunotherapy market. Elevated healthcare spending often aligns with an intensified emphasis on innovative and efficient treatment approaches, notably for prevalent conditions such as allergies. Allergy immunotherapy, offering long-term relief by targeting allergic disease root causes, stands to benefit from this heightened financial commitment to healthcare. Enhanced accessibility to immunotherapy treatments is expected, bolstering adoption rates and contributing significantly to overall market growth. Notably, the Ministry of Finance's Economic Survey of 2022 highlighted India's increased public healthcare expenditure, reaching 2.1% of GDP in 2021-22 from 1.8% in 2020-21. Additionally, according to a survey by Willis Towers Watson Public Limited Company, global healthcare benefit costs surged from 8.2% in 2021 to 8.8% in 2022, with expectations of further growth to an average of 10% in 2023. This surge in healthcare expenditure underpins the anticipated expansion of the allergy immunotherapy market in the forecast period.

Prominent entities within the allergy immunotherapy market are at the forefront of technological innovation, introducing cutting-edge products such as artificial intelligence (AI)-powered allergy component testing to fortify their market standing. This groundbreaking testing platform, rooted in Component Resolved Diagnostics (CRD), represents a novel approach to diagnosing diverse allergy forms. For example, in May 2023, Metropolis Healthcare Limited, an Indian-based medical laboratory company, unveiled the AI-powered allergy component testing. This fourth-generation allergy testing technology utilizes Artificial Intelligence (AI) to aid clinicians in making informed clinical decisions. It offers comprehensive insights, aiding in the selection and optimization of treatment paths for allergic conditions. Moreover, its predictive capabilities extend to determining the efficacy of allergy vaccinations, delineating their effectiveness, and guiding the course of immunotherapy treatments.

Key players in the allergy immunotherapy arena are embracing strategic partnerships as a means to broaden their capabilities and reach new heights. These alliances entail leveraging each other's strengths and resources to mutually benefit and achieve success. An illustration of this strategy unfolded in November 2022, as Vimian Group AB, a Sweden-based veterinary company, forged a partnership with Angany Inc., a Canada-based pharmaceutical company specializing in allergy immunotherapy. This collaborative endeavor aims to pioneer novel vaccines catering to allergy and atopic dermatitis in companion animals. Leveraging proprietary eBioparticle-Potentiated Immunotherapy technology, this partnership is focused on advancing the development of innovative vaccines tailored to address specific allergy-related concerns in companion animals.

Major companies operating in the allergy immunotherapy market report are LETI Pharma, Stallergenes Greer International AG, Allergy Therapeutics plc, ALK-Abello A/S, HAL Allergy B.V., DBV Technologies, Circassia Pharmaceuticals Inc., Jubilant HollisterStier LLC, Allergopharma GmbH & Co. KG, Biomay AG, Anergis SA, HollisterStier Allergy, Mylan N.V., Adamis Pharmaceuticals Corporation, Desentum Oy, WOLW Pharma Limited, AllerGenics Inc., Greer Laboratories Inc., Aimmune Therapeutics Inc., Reliant Laboratories Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Danaher Corporation, QIAGEN NV, Merck & Co. Inc., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, AstraZeneca plc, Sanofi SA, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd. .

Europe was the largest region in the allergy immunotherapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the allergy immunotherapy market report during the forecast period. The regions covered in the allergy immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the allergy immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allergy immunotherapy market includes revenues earned by entities by providing monoclonal antibodies and immune checkpoint inhibitors therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.